



La microchirurgie innovante du dos

Communiqué de presse

VEXIM presents its financial agenda for 2016

Toulouse, December 10, 2015 - VEXIM (FR0011072602 - ALVXM / PEA-PME eligible), a medical device company specializing in the minimally-invasive treatment of vertebral fractures, today announced its preliminary financial agenda for 2016.

ANNOUNCEMENT	DATE *
2015 Full-Year Sales	Thursday, January 14, 2016
2015 Full-Year Results	Wednesday, March 23, 2016
Q1 2016 Sales	Thursday, April 14, 2016
2016 Half-Year Sales	Wednesday, July 20, 2016
2016 Half-Year Results	Thursday, September 22, 2016
Q3 2016 Sales	Thursday, October 13, 2016

Financial year ended December 31

** Subject to modification. Press releases are distributed either before the financial markets opening, or after the closure.*

About VEXIM, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The company has specialized in the creation and marketing of minimally-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholder, Truffle Capital¹ and from BPI public subsidies, VEXIM has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 60 members on its staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland, the United Kingdom and United States, as well as distributors in Turkey, Argentina, Taiwan, Belgium, Estonia, Poland, Portugal, South Africa, Saudi Arabia, Colombia, Panama, Venezuela, Chile, Peru and Ecuador and in the following

¹ Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.

countries where the product is currently being registered: Mexico, Brazil. VEXIM has been listed on NYSE Alternext Paris since May 2012.

For further information, please visit www.vexim.com

SpineJack®, a revolutionary implant for treating Vertebral Fractures

The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column's optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by minimally-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral fractures and all patient morphologies.

SpineJack® technology benefits from the support of international scientific experts in the field of spinal surgery and worldwide patent protection through to 2029.

Contacts

VEXIM

Vincent Gardès

CEO

investisseur@vexim.com

Tel: +33 5 61 48 48 38

Alize RP

Relations presse

Caroline Carmagnol et Wendy Rigal

vexim@alizerp.com

Tél. : +33 1 44 54 36 66

+33 6 48 82 18 94

LifeSci Advisors LLC

Investor Relations

Michael Wood

www.lifesciadvisors.com

+1 646 597 6983



- **Name:** VEXIM
- **ISIN code:** FR0011072602
- **Ticker:** ALVXM

